Interní Med. 2007; 9(4): 188-191

Specific treatment of migraine

MUDr. Jiří Mastík
Neurologická klinika LF MU a FN u sv. Anny, Brno

Introduction of triptans, specific selective agonists 5-HT1B/1D receptors, represent a significant progress in acute treatment of migraine. Triptans found a broad application in the treatment, especially for moderate and severe migraine attacks, significantly shortened average length of migraine attack. When compared to non-specific antimigraine drugs, triptans lead to the economical savings. Differences in efficacy and safety among the triptans make the individually tailored therapy possible.

Keywords: headache, migraine, acute treatment, triptans, 5-HT1B/1D receptors

Published: June 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mastík J. Specific treatment of migraine. Interní Med. 2007;9(4):188-191.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: An overview. Eur Neurol 1991; 31: 339-344. Go to original source... Go to PubMed...
    2. Caro JJ, Getsios D, Raggio G, et al. Treatment of migraine in Canada with naratriptan: a cost-effectivness analysis. Headache 2001; 41: 456-464. Go to original source... Go to PubMed...
    3. Dahlöf C, Tansey MJB, et al. A randomized, double-blind comparison of sumatriptan and cafergot in the acute treatment of migraine. Eur Neurol 1991; 31: 314-322. Go to original source... Go to PubMed...
    4. Diener H-C. Pharmacological approaches to migraine. J Neural Transm 2003; (Suppl) 64: 35-63. Go to original source... Go to PubMed...
    5. Dočekal P, Keller O, Marková J, Opavský J. Bolesti hlavy. In: Rokyta R, Kršiak M, Kozák J. (Eds). Bolest. Praha: Tigis 2006: 461-477.
    6. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998; 13: 667-676. Go to original source... Go to PubMed...
    7. Ferrari MD. The war of the triptans. Teaching course, Syllabus EFNS, Lisbon 1999.
    8. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a metaanalysis of 53 trials. Lancet 2001; 358: 1668-1675. Go to original source... Go to PubMed...
    9. Géraud G, Kenwood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological and pharmacokinetic properties of triptans. Headache 2003; 43: 376-388. Go to original source... Go to PubMed...
    10. Headache classification subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia 2004; 24 (Suppl 1): 1-160.
    11. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999; 159: 813-818. Go to original source... Go to PubMed...
    12. Humphrey PPA, Feniuk W, Marriot AS, Tanner RJN, Jackson MR, Tucker ML. Preclinical studies of antimigraine drug, sumatriptan. Eur Neurol 1991; 31: 282-290. Go to original source... Go to PubMed...
    13. Chia Y-Ch, Lim S-H, Wang S-J, Cheong YM, Denaro J, Hettiarachchi J. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs. Headache 2003; 43: 984-990. Go to original source... Go to PubMed...
    14. Jackson NC. A comparison of oral eletriptan (20-80 mg) and oral sumatriptan (100 mg) in the acute treatment of migraine. Cephalalgia 1996; 16: 368.
    15. Marková J, Procházková M, Doležal T. Frovatriptan. Farmakoterapie 2006; 3: 265-270.
    16. Mastík J, Doležal T. Sumatriptan. Farmakoterapie 2006; 6: 626-631.
    17. Mastík J, Marková J, Doležil D, Dočekal P. Sledování dlouhodobé účinnosti a snášenlivosti eletriptanu v akutní léčbě migrény. Neurologie pro praxi 2006; 6: 330-332.
    18. Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacoterapy. Cephalalgia 1996; 16: 323-327. Go to original source... Go to PubMed...
    19. Moskowitz MA, Buzi MG. Evidence for 5-HT 1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991; 11: 165-168. Go to original source... Go to PubMed...
    20. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002; 42: 28-31. Go to original source... Go to PubMed...
    21. Ryan R, Géraud G, Goldstein J, et al. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002; 42 (Suppl 2): 584-592. Go to original source... Go to PubMed...
    22. Steiner TJ, Diener HC, MacGregor EA, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003; 23: 942-952. Go to original source... Go to PubMed...
    23. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: a systematic review based on numer needed to treat. Cephalalgia 1998; 18: 532-538. Go to original source... Go to PubMed...
    24. Tfelt-Hansen P, Saxena PR, Dahlöf C, Pascual J, Láinez M, Henry P, Diener H-C, Schoenen J, Ferrari MD, Goadsby PJ. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 2000; 123: 9-18. Go to original source... Go to PubMed...
    25. Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000; 20: 687-695. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.